AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16037107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol moistened with 3 ml of 5% acetic acid (group A, n = 33)
Number of subjects: 66
Study 16037107 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol moistened with 3 ml of saline (group B, n = 33)
Number of subjects: 66
Study 12074357 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 31
Study 12074357 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 31
Study 12074357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Candesartan 16 mg and Felodipine 5 mg
Number of subjects: 31
Study 10583039 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice (200 ml)
Number of subjects: 12
Study 10583039 — intervention group
Group type: COMPARATOR
Intervention: Water (200 ml)
Number of subjects: 12
Study 7671980 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotonic patients
Number of subjects: 14
Study 2402215 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPE training (N = 15)
Number of subjects: 43
Study 2402215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training (N = 14)
Number of subjects: 43
Study 2402215 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 14)
Number of subjects: 43
Study 6308970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive aftercare recruitment procedure
Number of subjects: 50
Study 6308970 — intervention group
Group type: COMPARATOR
Intervention: Regular clinic aftercare
Number of subjects: 50
Study 6308970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intensive and regular aftercare)
Number of subjects: 50
Study 30666826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 797
Study 30666826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 797
Study 30666826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to tofacitinib at month 3 or 6)
Number of subjects: 797
Study 30666826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg or 10 mg twice daily plus MTX
Number of subjects: 797
Study 29936695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated accelerated radiotherapy (HART)
Number of subjects: 89
Study 29936695 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CRT)
Number of subjects: 89
Study 29936695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HART and CRT
Number of subjects: 89
Study 26969758 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (Zilver PTX)
Number of subjects: 474
Study 26969758 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional Paclitaxel-eluting stent (Zilver PTX)
Number of subjects: 474
Study 26969758 — intervention group
Group type: COMPARATOR
Intervention: Standard care (PTA and provisional Zilver bare metal stent)
Number of subjects: 474
Study 26969758 — intervention group
Group type: COMPARATOR
Intervention: Provisional bare metal stent (BMS)
Number of subjects: 474
Study 25163948 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-hip approach (n=55)
Number of subjects: 143
Study 25163948 — intervention group
Group type: COMPARATOR
Intervention: Bauer approach (n=88)
Number of subjects: 143
Study 22285454 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal counseling procedure
Number of subjects: 154
Study 22285454 — intervention group
Group type: COMPARATOR
Intervention: No vocal counseling procedure
Number of subjects: 154
Study 19057387 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk intake (highest vs. lowest quintile)
Number of subjects: 26556
Study 19057387 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt intake (highest vs. lowest quintile)
Number of subjects: 26556
Study 19057387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream intake (highest quintile)
Number of subjects: 26556
Study 19057387 — intervention group
Group type: COMPARATOR
Intervention: Total dairy, low-fat milk, sour milk, cheese, ice cream, butter intake
Number of subjects: 26556
Study 20517331 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin-enriched and probiotic-supplemented formula (EF, Modilac Digest 1)
Number of subjects: 66
Study 20517331 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 66
Study 16137239 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade mobilisation techniques
Number of subjects: 92
Study 16137239 — intervention group
Group type: COMPARATOR
Intervention: Low-grade mobilisation techniques
Number of subjects: 92
Study 12171373 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 0
Study 12171373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 0
Study 12171373 — intervention group
Group type: COMPARATOR
Intervention: Standard care or other active interventions
Number of subjects: 0
Study 9610927 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% BCAA solution
Number of subjects: 6
Study 9610927 — intervention group
Group type: COMPARATOR
Intervention: 4% amino acid solution
Number of subjects: 6
Study 9610927 — intervention group
Group type: COMPARATOR
Intervention: Ringers lactate
Number of subjects: 6
Study 7821128 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 144
Study 7821128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea (glyburide, G)
Number of subjects: 144
Study 7821128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (M/G, G/M, MGH)
Number of subjects: 144
Study 7821128 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 144
Study 7821128 — intervention group
Group type: COMPARATOR
Intervention: Single-drug therapy (M or G)
Number of subjects: 144
Study 7821128 — intervention group
Group type: COMPARATOR
Intervention: Low-dose primary combination (MGL)
Number of subjects: 144
Study 7821128 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide alone (G)
Number of subjects: 144
Study 7821128 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone (M)
Number of subjects: 144
Study 7821128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (M and G)
Number of subjects: 144
Study 7821128 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall drug safety
Number of subjects: 144
Study 3270508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (500 mg orally every 4 hours for 3 days)
Number of subjects: 19
Study 3270508 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (100 mg/m2 per day by continuous infusion for 3 days)
Number of subjects: 19
Study 3270508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxyurea and etoposide (fixed molar ratio of 58.9:1)
Number of subjects: 19
Study 29782049 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM zolmitriptan 3.8 mg
Number of subjects: 159
Study 27345843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 180
Study 27345843 — intervention group
Group type: COMPARATOR
Intervention: Non-cetuximab
Number of subjects: 180
Study 24534036 — intervention group
Group type: EXPERIMENTAL
Intervention: N alpha methyl histamine (1 to 3 ug twice a week)
Number of subjects: 60
Study 24534036 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (120 mg/day)
Number of subjects: 60
Study 22382047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-Up Test (orthostatic challenge)
Number of subjects: 49
Study 23437548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine candidate (live attenuated oral Vibrio cholerae Ol El Tor, Ogawa strain 638)
Number of subjects: 21
Study 23437548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23437548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine candidate
Number of subjects: 21
Study 18522501 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine
Number of subjects: 2058
Study 18522501 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated vaccine
Number of subjects: 2058
Study 18522501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2058
Study 15681602 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy + Endocrine Therapy
Number of subjects: 200
Study 15681602 — intervention group
Group type: COMPARATOR
Intervention: Endocrine Therapy Alone
Number of subjects: 200
Study 15526517 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10641740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.4 ppm during 2 h)
Number of subjects: 16
Study 10641740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (after second exposure)
Number of subjects: 16
Study 9345414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine treatment
Number of subjects: 0
Study 9345414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1711156 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 211
Study 1711156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 6369527 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure breathing (0.4 kPa)
Number of subjects: 7
Study 6369527 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece and face mask without positive pressure
Number of subjects: 7
Study 30921650 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO‐SINGJT reference task
Number of subjects: 0
Study 30921650 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO‐CYC reference task
Number of subjects: 0
Study 30921650 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovelocity sprint cycling test (120 RPM)
Number of subjects: 0
Study 30921650 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoinertial acceleration sprint cycling test (0 to >150 RPM)
Number of subjects: 0
Study 29722727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh specimens assessed by raters including surgeons, pathologists, pathology residents, pathologists' assistants, and pathologists' assistant trainees.
Number of subjects: 37
Study 29722727 — intervention group
Group type: EXPERIMENTAL
Intervention: Postfixation specimens assessed by pathologists and pathologists' assistants.
Number of subjects: 37
Study 29722727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologists' assistants grading specimens postfixation.
Number of subjects: 37
Study 29722727 — intervention group
Group type: COMPARATOR
Intervention: Comparison of agreement between different rater groups.
Number of subjects: 37
Study 27608067 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended practice without aids
Number of subjects: 0
Study 27608067 — intervention group
Group type: EXPERIMENTAL
Intervention: External aids combined with extended practice
Number of subjects: 0
Study 27608067 — intervention group
Group type: EXPERIMENTAL
Intervention: External aids with limited practice and instructions removing perceived memory requirements
Number of subjects: 0
Study 24491075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 115
Study 24491075 — intervention group
Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 115
Study 22959881 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prednisolone phosphate 1%
Number of subjects: 500
Study 22959881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 21149918 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily lamivudine
Number of subjects: 41
Study 21149918 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily abacavir
Number of subjects: 41
Study 21149918 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily lamivudine
Number of subjects: 41
Study 21149918 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily abacavir
Number of subjects: 41
Study 21149918 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily lamivudine and abacavir
Number of subjects: 41
Study 17482560 — intervention group
Group type: EXPERIMENTAL
Intervention: State guilt induction
Number of subjects: 0
Study 17482560 — intervention group
Group type: EXPERIMENTAL
Intervention: State anxiety induction
Number of subjects: 0
Study 17482560 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral affect induction
Number of subjects: 0
Study 16597777 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 16597777 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 11254911 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 62
Study 11254911 — intervention group
Group type: COMPARATOR
Intervention: No lipid lowering therapy
Number of subjects: 62
Study 9647153 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (100 mg suppositories)
Number of subjects: 100
Study 9647153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8090921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoteridol at standard dose (0.1 mmol/kg)
Number of subjects: 95
Study 8090921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoteridol at triple dose (0.3 mmol/kg)
Number of subjects: 95
Study 8090921 — intervention group
Group type: COMPARATOR
Intervention: Both doses of gadoteridol
Number of subjects: 95
Study 2531389 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy (n = 26 after exclusions)
Number of subjects: 55
Study 2531389 — intervention group
Group type: COMPARATOR
Intervention: Surgery (ligation of the esophagus on clip) (n = 24 after exclusions)
Number of subjects: 55
Study 1097489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 159
Study 1097489 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone-alka
Number of subjects: 159
Study 31815981 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision‐assisted orthodontics
Number of subjects: 20
Study 31815981 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthodontics
Number of subjects: 20
Study 31654994 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA (n=83)
Number of subjects: 129
Study 31654994 — intervention group
Group type: COMPARATOR
Intervention: INSURE (n=46)
Number of subjects: 129
Study 28917695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 28917695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 28917695 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0
Study 28917695 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 25819139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1441
Study 25819139 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1441
Study 23723278 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (fixation of the clavicular fracture)
Number of subjects: 25
Study 23723278 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 25
Study 21842003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage early loaded implants
Number of subjects: 30
Study 21842003 — intervention group
Group type: COMPARATOR
Intervention: 2-stage early loaded implants
Number of subjects: 30
Study 19570389 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous radiofrequency ablation combined with TriVex
Number of subjects: 150
Study 19570389 — intervention group
Group type: COMPARATOR
Intervention: Traditional stripping operation combined with TriVex
Number of subjects: 150
Study 17943677 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote administration of the Functional Reach Test (FRT)
Number of subjects: 26
Study 17943677 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote administration of the European Stroke Scale (ESS)
Number of subjects: 26
Study 17943677 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face administration of the Functional Reach Test (FRT)
Number of subjects: 26
Study 17943677 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face administration of the European Stroke Scale (ESS)
Number of subjects: 26
Study 15257995 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, 60-Hz nighttime magnetic field exposure (0.5-1.0 micro T above ambient levels)
Number of subjects: 0
Study 15257995 — intervention group
Group type: COMPARATOR
Intervention: Ambient magnetic field levels (0.001-0.50 micro T)
Number of subjects: 0
Study 11340701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP) 400 micrograms/day
Number of subjects: 54
Study 11340701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patch (Dermestril) with 25 micrograms/day
Number of subjects: 24
Study 9272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patch (Dermestril) with 50 micrograms/day
Number of subjects: 24
Study 9272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patch (Dermestril) with 100 micrograms/day
Number of subjects: 24
Study 9272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patch (Dermestril)
Number of subjects: 24
Study 8409874 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medical record system with voice input
Number of subjects: 3
Study 8409874 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medical record system with keyboard input
Number of subjects: 3
Study 8409874 — intervention group
Group type: COMPARATOR
Intervention: Standard paper-and-pencil charting system
Number of subjects: 3
Study 3485521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 60
Study 3485521 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30875684 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for recurrent lumbar disc herniation
Number of subjects: 24
Study 30875684 — intervention group
Group type: COMPARATOR
Intervention: Control group (31 healthy subjects)
Number of subjects: 24
Study 26932835 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-PACK programme
Number of subjects: 8877
Study 26932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplementation studies
Number of subjects: 8877
Study 26932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation plan
Number of subjects: 8877
Study 24618266 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+ETN
Number of subjects: 110
Study 24618266 — intervention group
Group type: COMPARATOR
Intervention: MTX+PBO
Number of subjects: 110
Study 21920711 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI monotherapy (escitalopram plus placebo)
Number of subjects: 665
Study 21920711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antidepressant medication (bupropion-sustained release plus escitalopram or venlafaxine-extended release plus mirtazapine)
Number of subjects: 665
Study 21920711 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive severity
Number of subjects: 665
Study 19191775 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 68
Study 19191775 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone proprionate nasal drops (FPND) 400 microg b.i.d.
Number of subjects: 68
Study 17927437 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight speech enhancement methods (four classes of algorithms: spectral subtractive, sub-space, statistical model based, and Wiener-type algorithms)
Number of subjects: 0
Study 17927437 — intervention group
Group type: EXPERIMENTAL
Intervention: Subspace algorithm
Number of subjects: 0
Study 17927437 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of consonant confusion matrices
Number of subjects: 0
Study 15309376 — intervention group
Group type: EXPERIMENTAL
Intervention: LY354740 (100 mg)
Number of subjects: 19
Study 15309376 — intervention group
Group type: EXPERIMENTAL
Intervention: LY354740 (400 mg)
Number of subjects: 19
Study 15309376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15309376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 19
Study 14641843 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 0
Study 14641843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 0
Study 14641843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10389719 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm2 patch of 0.025 mg estradiol and 0.125 mg norethisterone acetate
Number of subjects: 441
Study 10389719 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-cm2 patch of 0.05 mg estradiol and 0.25 mg norethisterone acetate
Number of subjects: 441
Study 10389719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (2 mg estradiol and 1 mg norethisterone acetate)
Number of subjects: 441
Study 8876026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 8876026 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 0
Study 1496227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy and local breast irradiation (LXRT)
Number of subjects: 488
Study 6651519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (maintained regimen)
Number of subjects: 20
Study 6651519 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (stopped 6 hours before surgery)
Number of subjects: 20
Study 3511932 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine plus potassium chloride
Number of subjects: 20
Study 3511932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus potassium chloride
Number of subjects: 20
Study 3511932 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine
Number of subjects: 20
Study 3511932 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 20
Study 31758571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (10 days of rabeprazole, clarithromycin, amoxycillin, and tinidazole; 60 pills, cost US$10)
Number of subjects: 313